NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa

The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa

Global and Local Challenges and Solutions

Summary of a Joint Workshop

; .

Washington (DC): National Academies Press (US); .
ISBN-13: 978-0-309-16024-7ISBN-10: 0-309-16024-3

Excerpt

In recognition of the grave threat posed worldwide by drug-resistant tuberculosis (TB), in November 2008 the Institute of Medicine's (IOM's) Forum on Drug Discovery, Development, and Translation held a workshop titled “Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge,” which brought together experts in drug-resistant TB and public health to speak frankly and openly about the problem. That workshop led to plans for four additional workshops in countries with a high burden of drug-resistant TB. The first of these workshops, summarized in this volume, was held in Pretoria, South Africa, on March 3–4, 2010, with subsequent workshops being planned for Russia, China, and India. The workshop brought together about 65 disease experts, community leaders, policy makers, and patient advocates from South Africa, other countries in southern Africa, and the United States for 2 days of intensive discussions. The workshop was supported in part by the Doris Duke Foundation, by the Howard Hughes Medical Institute, and by the U.S. Department of State.

Contents

Rapporteurs: Steve Olson, Yeonwoo Lebovitz, and Anne Claiborne

This study was supported by Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and 223001003T), the U.S. State Department (S-LMAQM-08-GR-071), the American Diabetes Association, the American Society for Microbiology, Amgen Inc., the Association of American Medical Colleges, Bristol-Myers Squibb, the Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, the Critical Path Institute, the Doris Duke Charitable Foundation, Eli Lilly & Co., GlaxoSmithKline, Howard Hughes Medical Institute, Johnson & Johnson, Novartis Pharmaceuticals Corporation, and Pfizer, Inc. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project.

Suggested citation:

IOM (Institute of Medicine). 2011. The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa: Global and Local Challenges and Solutions: Summary of a Joint Workshop. Washington, DC: The National Academies Press.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

Copyright © 2011, National Academy of Sciences.
Bookshelf ID: NBK55582PMID: 21678633DOI: 10.17226/12993

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (750K)
  • Disable Glossary Links

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...